Xagrotin

**Xagrotin** is an investigational multi-herb medicinal product developed by Biomad for treatment of early, non-severe COVID-19. It is described as a mixture of local plants from the Zagros Mountains in Kurdistan; public materials describe a formulation containing six plants and report exploratory in silico, in vitro, in vivo, and clinical evaluations. Its precise active-constituent composition and validated molecular mechanism have not been publicly established. ([cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/93/NCT05017493/SAP_001.pdf)) Xagrotin was studied in a completed Phase 1/2 outpatient COVID-19 trial and subsequently registered for a Phase 3 trial in non-severe SARS-CoV-2 outpatients sponsored by Biomad. ([ichgcp.net](https://ichgcp.net/clinical-trials-registry/NCT05017493))

Other names

Xagrotin